Cerulean Pharma (NASDAQ:CERU) major shareholder Eli Lilly and Co (NYSE:LLY), acquired 733,445 shares of the company’s stock in a transaction dated Tuesday, April 15th. The stock was purchased at an average price of $7.00 per share, for a total transaction of $5,134,115.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC. Eli Lilly and Co (NYSE:LLY), shares after opening at $58.31 moved to $59.18 on last trade day and at the end of the day closed at $58.68. Company price to sales ratio in past twelve months was calculated as 2.84 and price to cash ratio as 12.17. Eli Lilly and Co (NYSE:LLY), showed a negative weekly performance of 2.13%.
Celgene Corporation (NASDAQ:CELG), Director Ernest Mario bought 1,000 shares of the company’s stock in a transaction that occurred on 29, September 2013. The stock was purchased at an average cost of $123.72 per share, for a total transaction of $123,720.00. Celgene Corporation (NASDAQ:CELG), shares fell 2.47% in last trading session and ended the day on $141.25. Celgene Corporation (NASDAQ:CELG), return on equity ratio is recorded as 25.80% and its return on assets is 11.50%. Celgene Corporation (NASDAQ:CELG), yearly performance is 19.42%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO), CEO Jong Joseph Kim bought 25,000 shares of the company’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $56,250.00. Following the transaction, the chief executive officer now directly owns 5,965,809 shares of the company’s stock, valued at approximately $13,423,070. The purchase was disclosed in a legal filing with the Securities & Exchange Commission. Inovio Pharmaceuticals Inc (NYSEMKT:INO), shares moved down 0.38% in last trading session and was closed at $2.60, while trading in range of $ 2.52 – 2.68. Inovio Pharmaceuticals Inc (NYSEMKT:INO), year to date (YTD) performance is -10.34%.
Opko Health Inc. (NYSE:OPK), CEO Phillip Md Et Al Frost purchased 16,500 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were purchased at an average price of $9.27 per share, with a total value of $152,955.00. Following the acquisition, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $18,424,125. The transaction was disclosed in a document filed with the SEC. Opko Health Inc. (NYSE:OPK), weekly performance is -1.08%. On last trading day company shares ended up $8.24. Opko Health Inc. (NYSE:OPK), distance from 50-day simple moving average (SMA50) is -8.87%. Analysts mean target Price for the company is $12.50.
Leave a Reply